aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT(TM) Study of Efzofitimod in Pulmonary Sarcoidosis

Stock Information for aTyr Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About aTyr Pharma Inc.

aTyr Pharma to Present at the LD Micro Main Event XVII in October
aTyr Pharma's Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
aTyr Pharma to Participate in September Investor Conferences
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update 
aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations
aTyr Pharma Announces Research Study with Stanford Medicine
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from "LIFE" to "ATYR"

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.